NCT07248839

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Mild and Moderate Hepatic Impairment

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the pharmacokinetic and safety of BMS-986435 in participants with normal hepatic function and participants with different degrees of hepatic impairment

Conditions

• Healthy Volunteers
• Hepatic Impairment

Interventions

Type	Name	Description
DRUG	BMS-986435	Specified dose on specified days

Timeline

• Start date: 2025-12-15
• Primary completion: 2026-04-06
• Completion: 2026-04-06
• First posted: 2025-11-25
• Last updated: 2025-11-25

Regulatory

• FDA-regulated drug study